Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer
Listen to this summary
The authors aimed to evaluate the long-term efficacy of adjuvant S-1 in improving overall survival (OS) in patients with resected biliary tract cancer (BTC) compared to observation alone. The 5-year follow-up results from the ASCOT trial demonstrated that S-1 significantly improved OS (64% vs. 52%) and median OS (8.2 years vs. 5.9 years), confirming its sustained survival benefit and supporting its use as a standard treatment for resected BTC.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of clinical oncology : official journal of the American Society of Clinical Oncology
View all →Sep 22, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi
Sep 22, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
When Survival Separates
Sep 21, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study
Sep 18, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care
Sep 16, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial
Sep 15, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments
More in Pediatrics
View all →Sep 23, 2026 · The New England journal of medicine
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma
Sep 23, 2026 · Pediatric nephrology (Berlin, Germany)
IPNA clinical practice recommendations for the management of aHUS and secondary TMA in children
Sep 23, 2026 · American journal of respiratory and critical care medicine
Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP
Sep 23, 2026 · The New England journal of medicine
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Sep 23, 2026 · American journal of respiratory and critical care medicine
Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Sep 23, 2026 · The New England journal of medicine
Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
